GT201 Injection in Combination with Teraplizumab Injection for Treatment of Patients with Non-small Cell Lung Cancer

This trial is testing a combination of a cell therapy (GT201, a type of engineered immune cell therapy) with an immunotherapy drug (teraplizumab) for patients with non-small cell lung cancer (NSCLC). **You may be eligible if...** - You are 18 to 70 years old - You have non-small cell lung cancer that has progressed - You are in reasonably good general health - Your expected survival is at least 12 weeks - Your cancer has at least one measurable tumor on imaging **You may NOT be eligible if...** - You have uncontrollable cancer-related pain - You have a known mental illness, alcohol dependency, or substance abuse issues - You are pregnant, breastfeeding, or planning to become pregnant within 1 year of treatment - You have received another experimental treatment within 4 weeks before starting this trial Talk to your doctor to see if this trial is right for you.